SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is surging as strong Azure cloud growth and a clear focus on AI monetization help soothe investor anxiety regarding capital expenditures. The community is actively debating whether this performance marks a broader market turnaround or if it will be hindered by headwinds from other underperforming big-tech names.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is facing downward pressure as investors react to disappointing full-year guidance and concerns over net yield, which overshadowed a reported earnings beat. While the stock is struggling with negative sentiment and fuel cost volatility, the community remains divided, with some investors viewing the price drop as a buying opportunity based on long-term turnaround potential and strategic leadership changes.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor attention driven by a series of upsized, AAA-rated ABS deals and positive credit outlooks, leading many in the community to highlight the company's strong fundamentals and undervalued valuation relative to fintech peers. Despite this performance, the stock faces ongoing volatility from macro headwinds and persistent short-selling, causing retail investors to debate whether the current price represents a prime accumulation zone ahead of upcoming earnings.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the company's announcement of marketing authorization in the UAE for Anktiva, which marks a significant expansion of its regulatory footprint into its 34th country. Community sentiment is mixed, with long-term investors highlighting the broader global validation of the drug while others express frustration over the timing of news delivery and persistent short interest.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is surging following a blockbuster earnings report that featured record revenue and raised full-year guidance, fueled by intense demand for onsite power from AI hyperscalers. The community is actively debating the stock's future trajectory, weighing the impressive fundamental growth against broader market volatility and institutional influence.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing sharp downward pressure as investors express concerns over the company's aggressive capital expenditure plans and limited near-term visibility into AI monetization. While some community members view the pullback as a potential buying opportunity given the company's strong ad revenue fundamentals, others are actively debating whether the high spending levels will yield sufficient returns or continue to erode free cash flow.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to upcoming Q3 data readouts for its VK2735 obesity drug, with investors closely watching the maintenance dosing study and oral pipeline progress. While community sentiment is divided between optimism over the drug's best-in-class potential and frustration regarding the CEO's communication style, insider activity, and potential future share dilution, significant interest persists in the firm's strategic path toward commercialization or a potential partnership.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are under intense pressure as traders brace for upcoming earnings, with social sentiment divided between excitement over record revenue metrics and frustration over the stock's recent volatility. Investors are actively debating the impact of crypto revenue, the expansion of new financial products, and whether the platform's strong growth figures can overcome broader market headwinds.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holdings is surging following strong half-year financial results, where the company significantly exceeded expectations and raised its full-year guidance for operating profit and free cash flow. Investors are heavily focused on the company's momentum in its SMR nuclear energy division and upcoming contract signings with major hyperscalers, signaling a robust outlook for its transformation strategy.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm faces mixed market sentiment as investors weigh long-term growth opportunities in automotive, AI, and edge computing against near-term handset weakness and margin pressures. The community remains divided between those viewing current price levels as an oversold buying opportunity and those concerned about the company's ability to maintain momentum amidst a shifting semiconductor landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

James

eXoZymes (Nasdaq: $EXOZ ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company&#39;s first proof point. 
 
eXoZymes Inc. is a B2i Digital Featured Company. See the company&#39;s profile at https://b2idigital.com/exozymes-1 
 
&quot;It is fundamentally different from GLP-1 drugs,&quot; Perryman said. &quot;GLP-1s reduce appetite, whereas NCT and its activation of HNF4 alpha improves mitochondrial biogenesis and mitochondrial activity, essentially improving how the body burns fat.&quot; 
 
From the same segment: 
• NCT activates HNF4 alpha, a master metabolic control switch, rather than acting on a single downstream symptom 
• In controlled preclinical models on identical diets, eXoZymes reported 30% to 40% less weight gain in the mouse population 
• The company also observed improved mitochondrial function and reduced liver fat, consistent with hitting a central regulatory pathway 
 
Watch the full webinar: https://youtu.be/OmH3TaaMT20 
 
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. 
 
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital&#39;s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. 
 
$DNLI, $TWST, $DNA, $ARKG

eXoZymes Inc. management brings together biotechnology and commercial expertise. The team combines scientific leadership from UCLA with business executives experienced in scaling technology companies, leveraging deep knowledge in enzyme engineering, artificial intelligence, and biomanufacturing to develop and commercialize cell-free production solutions for partners worldwide. The eXoZymes Inc.

eXoZymes Inc. | Nasdaq: EXOZ | B2i Digital Featured Company

Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perryman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1

eXoZymes (Nasdaq: EXOZ) Webull Biotech Webinar | Unlocking Nature's Molecules

eXoZymes is redefining how complex molecules are discovered, manufactured, and commercialized. Its AI-enhanced, cell-free biomanufacturing platform turns rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. By embedding manufacturability directly into discovery, eXoZymes collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths.

Home - eXoZymes leading the next generation of biomanufacturing

b2i digital - connecting companies and investors through digital marketing, investor conferences, and direct introductions and meetings.

B2i Digital - Connecting companies and investors

Disclaimer - Content is provided "as is" by companies featured on the site. Conduct a trusted advisory before making investments.